By a News Reporter-Staff News Editor at Drug Week -- A new study on Diet and Nutrition Disorders is now available. According to news originating from Houston, Texas, by NewsRx correspondents, research stated, "PPAR gamma nuclear receptor agonists have been shown to attenuate macrophage inflammatory responses implicated in the metabolic complications of obesity and in atherosclerosis. However, PPAR gamma agonists currently in clinical use, including rosiglitazone (RSG), are often associated with severe side effects that limit their therapeutic use."
Our news journalists obtained a quote from the research from the University of Texas, "Here, 200 nm PLGA/PVA nanospheres were formulated for the systemic delivery of RSG specifically to macrophages. RSG was encapsulated with over 50% efficiency in the hydrophobic PLGA core and released specifically within the acidifying macrophage phagosomes. In bone marrow derived macrophages, RSG-loaded nanoparticles (RSG-NPs) induce a dose dependent upregulation (1.5 to 2.5-fold) of known PPAR gamma target genes, with maximal induction at 5 mu M; and downregulate the expression of genes related to the inflammatory process, with a maximum effect at 10 mu M. In Ldlr(-/-) mice fed high fat diet, treatment with RSG-NPs alleviated inflammation in white adipose tissue and liver but, unlike treatment with free RSG, did not alter genes associated with lipid metabolism or cardiac function, indicating a reduction in the RSG side effect profile."
According to the news editors, the research concluded: "These biocompatible, biodegradable RSG-NPs represent a preliminary step towards the specific delivery of nuclear receptor agonists for the treatment of macrophage-mediated inflammatory conditions associated with obesity, atherosclerosis and other chronic disease states."
For more information on this research see: Rosiglitazone-loaded nanospheres for modulating macrophage-specific inflammation in obesity. Journal of Controlled Release, 2013;170(3):460-468. Journal of Controlled Release can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Journal of Controlled Release - www.elsevier.com/wps/product/cws_home/502690)
The news correspondents report that additional information may be obtained from D. Di Mascolo, Univ Texas MD Anderson Canc Center, Dept. of Biostat, Houston, TX 77030, United States. Additional authors for this research include C.J. Lyon, S. Aryal, M.R. Ramirez, J. Wang, P. Candeloro, M. Guindani, W.A. Hsueh and P. Decuzzi (see also Diet and Nutrition Disorders).
Keywords for this news article include: Texas, Houston, Obesity, Genetics, Nanophere, Treatment, Bariatrics, Immunology, Nanosphere, PPAR gamma, Macrophages, Inflammation, United States, Overnutrition, Nanotechnology, DNA-Binding Proteins, Emerging Technologies, Transcription Factors, North and Central America, Diet and Nutrition Disorders
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC